What You Need to Know: Prostate-specific antigen (PSA) screening is controversial, but a new study shows PSA is associated with a lasting reduction in your risk of dying from prostate cancer, with an increased effect at 13 years compared with nine or 11 years.
The Study: European Randomised study of Screening for Prostate Cancer (ERSPC) is a multi center, randomized trial assessmentt of PSA testing in eight European countries for men ages 50 to 72. Data truncated at 13 years.
Results: At 13 years, the absolute risk reduction of death from prostate cancer was 0.11 per 1,000 person-years or 1.28 per 1,000 men randomized.
My Take: In this update, the ERSPC confirms a meaningful reduction in prostate cancer mortality attributable to the PSA blood test, with an even greater effect at 13 years compared to 9 and 11 years. While the use of screening PSA is controversial, this well-done study points to a PSA-linked reduction in the risk of prostate-related death. I’m Dr. Michael Hunter.
The small print: The material presented herein is informational only, and is not designed to provide specific guidance for an individual. Please check with a valued health care provider with any questions or concerns. As for me, I am a Harvard- , Yale- and UPenn-educated radiation oncologist, and I practice in the Seattle, WA (USA) area. I feel genuinely privileged to be able to share with you. If you enjoyed today’s offering, please consider clicking the follow button at the bottom of this page.
Available now: Understand Colon Cancer in 60 Minutes; Understand Brain Glioma in 60 Minutes. Both can be found at the Apple Ibooks store. Coming Soon for iPad: Understand Breast Cancer in 60 Minutes; Understand Colon Cancer in 60 Minute; Understand Colon Cancer in 60 Minutes; Understand Brain Glioma in 60 Minutes. Thank you.
Reference: The Lancet, Early Online Publication, 7 August 2014.